GLP-1
59 independently sourced, verified news trends involving GLP-1.
Coverage evidence
This hub is built from stories supported by at least four independent sources and accepted by Newsylist's verification pass. Qualifying coverage spans 3 news categories, from Jun 25, 2026 through Nov 20, 2026.
Open any card for the source list, timeline and coverage-velocity evidence. Raw detections and extractive-only records are excluded from this page.
GLP-1 poison calls surge in Georgia as experts warn about unapproved weight-loss drugs - WSB-TV
The GLP-1 boom has a dark side
Millions of Americans are not taking their GLP-1 drugs as prescribed
Some people are having hallucinations and other psychotic symptoms after stopping GLP-1 drugs
FDA warns GLP-1 drugs carry potential risk of rare eye condition
FDA tells GLP-1 makers to warn of potential vision loss side effect
An ‘Ozempic baby boom’? The GLP-1 pregnancy plot twist : Short Wave
Your job-based insurance cut GLP-1 coverage. Here are some options
Keeping the Weight Off After Stopping a GLP-1
NEWSLETTER: GLP-1 drugs help control prediabetes better than current standard medicine
Chrissy Metz Shares the Best Results of GLP-1 Medication Besides Weight Loss
Earnings live updates: Eli Lilly stock pops as strong GLP-1 drug demand lifts results, ServiceNow stock plunges
31 Shocking GLP-1 Side Effects That Have Nothing To Do With Weight Loss
GLP-1 drug coverage is being dropped by employer plans: What to know about 2027 weight-loss options
Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction
Is my GLP-1 safe? What to know about FDA's crackdown on copycat drugs
Millions of Surgery Records Raise New Questions About GLP-1 Drugs
GLP-1 injections recalled nationwide. See affected products
15% Of Americans Have Taken A GLP-1, And Dermatologists Now Have A Timeline For When The Hair Goes
GLP-1 weight-loss drugs slow biological aging, recent studies show
GLP-1 drugs can ‘reverse biologic aging’ by two to three years, say drug companies
Over 15M people take GLP-1 drugs in America and 54% agree on same issue
'Ozempic babies' are real — here's what doctors want you to know about fertility and GLP-1 drugs
Probing the many benefits of GLP-1 receptor agonists
WHO endorses lifestyle changes over GLP-1 drugs in child obesity fight
Nail detachment over four times more common among GLP-1 users, first controlled study finds
Dad claims he went suddenly, permanently blind from Ozempic — in one of hundreds of lawsuits against GLP-1 makers
Does GLP-1 use result in significant hair loss?
McDonald's is exploring ways to attract GLP-1 users
GLP-1 prescriptions for people with no medical need are climbing
GLP-1 makers Novo, Eli Lilly sued over sudden loss of vision in patients
‘Boom, lights out’: Massachusetts man shares sudden blindness journey after taking GLP-1
The company behind a new GLP-1 pill is betting $6.5 billion on Houston
Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
For Food Companies, Shifts From GLP-1 Use Are Hard to Digest
Large genetic study links GLP-1 receptor activation to improved mental well-being
What Really Disappears When You Lose Weight on GLP-1 Drugs?
GLP-1 drugs dubbed ‘fountain of youth’ as doctors share surprising benefits beyond weight loss
Researchers find new benefits, risks in GLP-1 weight loss drugs
Scientists uncover unexpected benefits and new risks surrounding widely used GLP-1 weight loss medications.
GLP-1 Drugs May Have a Hidden Effect on Your Eyes, Study Finds
New safety guidance and a lawsuit spotlight a possible eye‑risk link in popular GLP-1 weight‑loss drugs.
GLP-1 weight loss drugs: What experts say about keeping weight off after stopping
Use of GLP-1 weight loss medications has reached a new high in the United States, sparking debate over long-term efficacy and accessibility.
One in eight U.S. adults uses GLP-1 drugs; Medicare now opens weight-loss access
Medicare now provides access to GLP-1 weight-loss drugs as utilization rates among U.S. adults reach one in eight.
Compounded GLP-1 drugs creating concern among doctors and FDA
Compounded GLP-1 weight‑loss drugs face mounting scrutiny as doctors and regulators flag safety concerns.
Weight-loss jab users warned about relationship side effect no one prepares you for
GLP‑1 weight‑loss drugs are reshaping women’s marriage prospects and job markets, while sparking warnings about unseen relationship strain.
Scientists Searching 6,000 Drugs For Anti-Aging Properties Found One Hiding in Plain Sight
Researchers identify existing medications, including GLP-1 drugs and nasal sprays, as potential candidates for slowing biological aging processes.
Rare eye disorder linked to Ozempic-like medications
Regulators and health advisors are warning of a rare but severe risk of vision loss associated with GLP-1 weight-loss medications.
GLP-1 drugs linked to 17% drop in worker sick leave, new economic study finds
A new economic study suggests a correlation between the use of GLP-1 weight-loss drugs and a 17% reduction in employee sick leave.
Novo sues Lilly, claiming misleading ads in weight-loss drug battle
Novo Nordisk has filed a lawsuit against Eli Lilly over allegations of false and misleading advertising regarding weight-loss drug efficacy.
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging the company used deceptive and false advertising regarding GLP-1 weight-loss medications.
24 GLP-1 Users Reveal The Good, The Bad, And The Shocking Side Effects
GLP-1 weight-loss medications are seeing a massive surge in adoption, sparking debates over side effects and social disclosure.
Does stopping a GLP-1 really doom you to regain all the weight?
Recent studies examine the long-term impact of discontinuing GLP-1 weight-loss medications like Ozempic and Wegovy.
Why your health plan doesn’t cover GLP-1s, according to a top insurance exec
Rising demand for GLP-1 weight-loss medications is straining budgets and prompting insurers and employers to limit coverage.
New weight loss pill that’s beating oral Ozempic
New oral GLP-1 receptor agonists are emerging as powerful alternatives to existing weight-loss medications in recent clinical trials.
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Novo Nordisk and Vivani have announced a partnership to develop a long-acting semaglutide implant designed to assist with long-term weight loss.
Delta rolls out new basic business, premium economy tickets
Delta Air Lines is introducing new, lower-cost ticket options for business and first-class cabins that come with reduced amenities.
Amid heat wave, doctors warn of health risks for people taking GLP-1 drugs
Medical professionals are warning patients on GLP-1 medications about increased health risks during the current heat wave.
Eli Lilly's Market Cap Balloons, Again, On This IPO's Setback
Eli Lilly's market capitalization has risen following a setback for Kailera's oral GLP-1 obesity drug trials in China.
Eli Lilly and Company (LLY) CEO on How GLP-1s Will Reshape America
Eli Lilly's CEO outlines the transformative potential of GLP-1s as new oral weight-loss medications enter development.